后PD-1/PD-L1抑制剂时代肿瘤治疗展望

Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era

免疫检查点抑制剂能够重启并维持肿瘤-免疫循环,使抗肿瘤免疫反应正常化。目前,以抗PD-1/PD-L1单抗为代表的免疫检查点抑制剂已显著改善多种恶性肿瘤患者的预后,是免疫治疗的新里程碑。然而,单独使用抗PD-1/PD-L1单抗有效率低,与手术、化疗、放疗和靶向治疗等传统治疗手段的联合应用展现出巨大潜力,且新的免疫检查点抑制剂单药或联合使用也在研究中,从而进入后抗PD-1/PD-L1单抗时代。然而,联合方式和生物标志物的筛选仍然是关注的焦点。本文就免疫检查点抑制剂治疗现状作简要综述并对后抗PD-1/PD-L1单抗时代进行展望。

Immune checkpoint inhibitors restart and maintain cancer-immunity circulation to normalize the anti-tumor immunity.Currently,anti-PD-1/PD-L1 antibodies,as new milestone in immunotherapy,have significantly improved the prognosis of patients with various malignant tumors.However,anti-PD-1/PD-L1 antibody alone exhibited a low response rate,and the combination of anti-PD-1/PD-L1 antibody with traditional therapies such as surgery,chemotherapy,radiotherapy and targeted therapy have shown great potential.As new immune checkpoint inhibitors or in combination therapy are on the way,tumor immunotherapy is entering the era of post-anti-PD-1/PD-L1 antibody.The methodology of combination therapy and biomarker screening remain the focus.This paper reviews the current status of immune checkpoint inhibitor therapy and makes a perspective for the future of post-anti-PD-1/PD-L1 antibody era.